about
Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT.A comparison of the distribution of necrotic core in bifurcation and non-bifurcation coronary lesions: an in vivo assessment using intravascular ultrasound radiofrequency data analysis.Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis.Guidelines on myocardial revascularization.Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).Comparison of Paclitaxel-Coated Balloon Treatment and Plain Old Balloon Angioplasty for De Novo Coronary Lesions.Serial Morphological Changes of Side-Branch Ostium after Paclitaxel-Coated Balloon Treatment of De Novo Coronary Lesions of Main Vessels.A Comparison of Peri-Procedural Myocardial Infarction between Paclitaxel-Coated Balloon and Drug-Eluting Stent on De Novo Coronary Lesions.Meditations on secondary revascularisation in the aftermath of the SYNTAX trial.Clinical indications for intravascular ultrasound imaging.Focus on the research utility of intravascular ultrasound - comparison with other invasive modalitiesNew concepts in the design of drug-eluting coronary stents.Progress in treatment by percutaneous coronary intervention: the stent of the future.A new tool for the risk stratification of patients with complex coronary artery disease: the Clinical SYNTAX Score.First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting.Roller coasters: a source of fun and tears.Association of Inter-Arm Systolic Blood Pressure Difference with Coronary Atherosclerotic Disease Burden Using Calcium Scoring.Gender differences in risk factors and clinical outcomes in young patients with acute myocardial infarction.Outcomes of Percutaneous Coronary Intervention Performed at Offsite Versus Onsite Surgical Centers in the United Kingdom.Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5,433 patients enrolled in contemporary coronary stent trials.Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial.Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents.Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.Bifurcation lesions: Functional assessment by fractional flow reserve vs. anatomical assessment using conventional and dedicated bifurcation quantitative coronary angiogram.Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions.The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial).The SYNTAX score revisited: a reassessment of the SYNTAX score reproducibility.How should I treat a complex Post-CABG patient?3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System iIVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process.Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry.Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: an analysis of the SYNTAX study.Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents.Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS trial.5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials.The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer.Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "all-come
P50
Q30513311-C745ECDA-B54C-4D2D-A5E0-A357E72F0E0FQ33706819-E96D8A6C-7565-49FF-862A-F9D906A18A65Q33905460-F2D1A8B7-F6A7-4A59-AB45-C0415980E1EFQ34134730-14A2C14B-4410-4967-B58B-630D7EBC5278Q35888976-FB3558D4-1D47-430B-BEE0-CF3390EC0B26Q36541536-194CF955-7FA5-4DA3-82D7-92A2CBB142AEQ36707886-4332380A-E99D-43DD-94BB-738D7B5FFBA5Q37438436-44CEEDEC-DEF9-4076-A8E0-5A90F999DAFAQ37593299-F4A8415C-19E3-4F22-84E7-68619D0E6759Q37811096-EA641A27-9739-450F-8AB8-57F3E661FDADQ37833156-90AA7E1B-6087-4FA1-9F1A-5E370DC1D394Q38082647-B703FAEE-960B-4C02-B503-686651440EADQ38207803-46B22052-CE53-4C44-8EFA-81DB88A3F291Q38371749-2BD31B7A-1651-4556-818F-FEADEC8C4247Q38398602-18A5CDA3-F9D7-44C3-9F01-2A4853CB89E9Q38467411-BA09DA34-D336-4814-8118-C7021C111C28Q38548447-DF8380B7-A8B9-4373-B378-1E5E8965F32FQ38632569-9F2EAA51-93C7-41CF-B9A9-668EB2718795Q39794388-E3745333-E03D-45D3-A7B9-EA86A72597C2Q40702536-809C55DF-A359-4B1F-A40B-631D7A661026Q41132544-96D06F9B-2012-4A7E-B0B6-EBC90A9BBAA5Q41984080-8C5567E5-76BD-44DC-AE02-23588056CA78Q41985436-E1A139A6-A5E4-4AE4-88AE-357FFD37FB58Q42801196-67948D32-D340-42CD-8263-E257751EAC1BQ42970472-A2B4C933-5A0C-4162-AF95-186F531BE8F0Q43005713-5D2288F3-FC07-4225-9C18-AFE657F8BAA5Q43016712-FEA785D2-C272-4E8A-98CB-404292C8B4F7Q43156154-62013D90-D964-4CD0-B418-CD7F6DCDDC4AQ43163852-A09330D4-E0C3-4636-9B8A-87F68B828A7FQ43166416-BB0E05D9-4966-4520-AB24-FC69B45A49E4Q43168443-8E2A158A-4E2D-4B2C-BA75-A702125A1085Q43175075-0C5C7F91-F384-47B5-973F-4FEFB17CE366Q43187374-59A4BDED-23CE-459D-A457-9A4214A0ECE6Q43276723-7A1892DA-0CE5-4164-A7E1-38B78B1773D7Q43443721-B8B384E7-9A7E-4C92-AB22-2A1BCEC9686CQ43510332-E8B14BF0-E46F-4FE3-8D38-9E18D35EB798Q44258662-623F366F-E426-47C2-A91D-E06B7B625B78Q44455469-5E60FDE9-09C3-42F9-91E4-DB77AAA6082EQ46201503-D1C37158-ED42-4946-B26C-C88A07C7B304Q46745525-9636C0FD-7575-4E05-8BC1-6325BA95CAED
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Scot Garg
@ast
Scot Garg
@en
Scot Garg
@es
Scot Garg
@nl
Scot Garg
@sl
type
label
Scot Garg
@ast
Scot Garg
@en
Scot Garg
@es
Scot Garg
@nl
Scot Garg
@sl
prefLabel
Scot Garg
@ast
Scot Garg
@en
Scot Garg
@es
Scot Garg
@nl
Scot Garg
@sl
P106
P21
P31
P496
0000-0002-8911-0278